Related Experiment Video

Updated: May 26, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Genetic polymorphism of MMP family and coronary disease susceptibility: a meta-analysis

Min Li1, Jingpu Shi, Lingyu Fu

  • 1Department of Clinical Epidemiology, The First Hospital of China Medical University, Shenyang, PR China.

Gene
|January 10, 2012
PubMed

Insights

Genetic variations in matrix metalloproteinase (MMP) genes show a moderate association with coronary disease risk. Specific MMP gene polymorphisms, particularly in MMP3 and MMP9, are linked to increased incidence, especially in Asian populations.

Area of Science:

  • Genetics
  • Cardiovascular Disease Epidemiology

Background:

  • The association between matrix metalloproteinase (MMP) gene polymorphisms and coronary heart disease (CHD) remains controversial.
  • Understanding these genetic links is crucial for identifying individuals at higher risk.

Purpose of the Study:

  • To conduct a comprehensive meta-analysis clarifying the association between MMP gene polymorphisms and coronary disease.
  • To evaluate the impact of specific MMP polymorphisms on CHD incidence.

Main Methods:

  • Systematic literature search of PubMed, Web of Science, and Cochrane databases.
  • Inclusion of 39 studies with 42,269 participants.
  • Meta-analysis using STATA 11 to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs).
  • Subgroup analysis by continent to assess regional variations.

Main Results:

  • Six MMP gene polymorphisms (MMP1-1607 1G/2G, MMP3-Gly45Lys, MMP3-376 G/C, MMP3-1171 5A/6A, MMP9-1562 C/T, MMP9-R279Q) showed a small to medium effect on coronary disease incidence.
  • No significant association was found for MMP1-519 A/G, MMP1-340 T/C, and MMP2-1306 C/T polymorphisms.
  • Subgroup analysis indicated a relation between MMP3-1711 5A allele, MMP9-1562 C allele, and coronary disease, particularly in Asian populations.

Conclusions:

  • This meta-analysis provides moderate evidence for an association between six common MMP gene polymorphisms and coronary disease.
  • Further research is needed to elucidate the distinct effects of these polymorphisms across different racial groups.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...